Oral small molecule GLP-1 receptor agonist aleniglipron in people with overweight or obesity: a randomized, double-blind, placebo-controlled phase 2b trial - Top-Institutions - MDSpire

Oral small molecule GLP-1 receptor agonist aleniglipron in people with overweight or obesity: a randomized, double-blind, placebo-controlled phase 2b trial

  • By

  • Julio Rosenstock

  • Ildiko Lingvay

  • Donna Ryan

  • Ania M. Jastreboff

  • Robert Kushner

  • Andres Acosta

  • Thomas C. Blevins

  • Melissa Choi

  • Faith L. Holmes

  • Timothy Smith

  • Lisa Connery

  • Yao Li

  • Mike Ke Liu

  • Aline Barth

  • Jamie Butcher

  • Antonio Civitarese

  • Huibin Yue

  • Blai Coll

  • June 5, 2026

  • 0 min

Share

Top Institutions in Endocrinology

Brief introduction explaining scope and methodology.

  • #1

    Mayo Clinic
    Mayo Clinic

    Rochester, Minnesota

    Key Differentiators

    • Endocrinology

  • #2

    Massachusetts General Hospital
    Massachusetts General Hospital

    Boston, Massachusetts

    Key Differentiators

    • Endocrinology

  • #3

    Cleveland Clinic
    Cleveland Clinic

    Cleveland, Ohio

    Key Differentiators

    • Endocrinology

Original Source(s)

Oral small molecule GLP-1 receptor agonist aleniglipron in people with overweight or obesity: a randomized, double-blind, placebo-controlled phase 2b trial

  • by Julio Rosenstock, Ildiko Lingvay, Donna Ryan, Ania M. Jastreboff, Robert Kushner, Andres Acosta, Thomas C. Blevins, Melissa Choi, Faith L. Holmes, Timothy Smith, Lisa Connery, Yao Li, Mike Ke Liu, Aline Barth, Jamie Butcher, Antonio Civitarese, Huibin Yue, Blai Coll

  • June 5, 2026

Related Content

Ensitrelvir Reduced COVID After Household Exposure

In SCORPIO-PEP, symptomatic COVID-19 occurred in 3% vs 9% of household contacts by day 10.

Visceral fat area and visceral-to-subcutaneous fat ratio are more strongly associated with residual cholesterol than conventional anthropometric indices in adults with type 2 diabetes

Association Between Metabolic Clusters and Microbial Age in High-Risk Populations for Diabetes and Their Potential Impact on Cardiovascular Disease Risk: Cross-Sectional Observational Study